Not a peep about Geron. He just launches into his boiler plate pump of ARWR. Is this and auto pump alias ?
Dog face. Go bark under a different tree. You are a STEM pumping fool.
Kolbert has an awful track record. He recommend selling CUR at 80 cents and recommended a buy on STEM at the same time when it was $1.70.
byecell. The second patient improving is huge in my view. If 10% of "complete" injury SCI patients experience improvement below the injury site then there was a 1 and 10 chance that it was not the scaffold with Jordan. Now with 2 patients simple statistics would show it is now a 1 and 100 chance that is was not the scaffold. Now lets see what happens with #3, 4 and 5. It could be a grand slam
The answer is NO.
ISCO roadmap does not include spinal cord therapy. Several other companies are already doing this.
Not likely at this point. NVIV is trying to determine efficacy of the scaffold and the stem cell companies are trying to determine efficacy of their cells. If you put them together now it would muddy the waters. Hopefully in the future though.
There is no more "just around the corner" for Geron. The Stem cell IP is gone and so are many of the dreamers. Geron has a big pharma partner and the time line for the new trials are fairly predictable unless there is expedited approval or another Imetelstat setback. The only potential major news this year will be the start of the phase 2 trial and additional Mayo data.. in particular the MDS data.
You are correct though. Yahoo MBs are filled with "pending news", "somebody knows something"... This nonsense accounts for most of the MB traffic.
Hmmm. I wonder what would have happened if the locals were cannibals ? How many decades would it have taken for the next lost Europeans to show up?
Regardless of how big of a jerk AF might be you can't sue him for being a jerk. He has to violate a law
You can't sue Adam F. for offering his opinion of the data contained in CUR's PR.
Thanks Michael. Hopefully we will get more detail around the results so we can get a better idea of how many patients can benefit from this therapy. I think the market reaction has to do with the perception that the process of trying to identify a subgroup is going to dramatically lengthen the clinical development process. Let's hope that is not the case. If it benefits 40% of patients it should be up to the patients to decide if the odds out weigh the risks. Good luck to you.
From the 8K. This statement is made in discussion of the "Co-Promotion Option" which the 8K says may not be transferable to the acquiring company. Likely the acquirer could care a less about this if they plan to bail on the J&J deal.
mdsamlwidow, Thanks for sharing your experience with your husband's cancer. mainecoast is like the family relative that no one cares to discuss. He's more concerned about his profit as he climbs in years and fears his time will run out before he enjoys his profit.
moneygrubber, couldn't agree more with your take on AF. He's a dude on the internet providing his brash opinion. If he was profiting from a drop in a stocks price he would have been in jail long ago.
He's been correct many times before and wrong at times also. The points/concerns he made about CUR's data are valid. He has simple pointed out what needs to be seen in the data that was not presented in the PR. More detail on the existing data and new data from the coming trial will be necessary... And I am very long this stock.